[Familial type III hyperlipoproteinemia].
Kataoka
S
S
Department of Internal Medicine, Hiroshima City Asa Hospital.
Egusa
G
G
D053329:Apolipoprotein E2; D001057:Apolipoproteins E / Q000235:genetics / Q000378:metabolism; D053298:Chylomicron Remnants; D002914:Chylomicrons / Q000378:metabolism; D004035:Diet Therapy; D005081:Exercise Therapy; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000175:diagnosis / Q000209:etiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008079:Lipoproteins, VLDL / Q000378:metabolism; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D011971:Receptors, Immunologic / Q000378:metabolism; D011973:Receptors, LDL / Q000378:metabolism
D053329:Apolipoprotein E2; D001057:Apolipoproteins E; D053298:Chylomicron Remnants; D002914:Chylomicrons; D019812:Heparan Sulfate Proteoglycans; D000960:Hypolipidemic Agents; D008079:Lipoproteins, VLDL; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D011971:Receptors, Immunologic; D011973:Receptors, LDL